On the organization of an early arthritis clinic

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 1, 2001, Pages 1-15

  Klareskog, Lars ^a   Nordmark, Birgitta ^a   Lindblad, Staffan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Early; Outcome; Recruitment; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; CYTOKINE; ETANERCEPT; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; INTERLEUKIN 10; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; CLINICAL TRIAL; DAY CARE; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; EARLY DIAGNOSIS; FUNCTIONAL ASSESSMENT; GOOD CLINICAL PRACTICE; HEALTH CENTER; HEALTH PROGRAM; HEREDITY; HUMAN; INCIDENCE; LONG TERM CARE; MEDICAL DOCUMENTATION; MEDICAL SPECIALIST; OCCUPATIONAL HEALTH; ORGANIZATION; OUTCOMES RESEARCH; PATIENT REFERRAL; PHYSICAL CAPACITY; PHYSIOTHERAPY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL CARE; REGISTER; REVIEW; RHEUMATOID ARTHRITIS; SOCIAL ASPECT; SWEDEN; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0035042527     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2000.0122     Document Type: Article

References (53)

1. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs)
2. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group
3. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy
4. Randomised comparison of combined step-down prednisolone, methorexate and sulphasalazine alone in early rheumatoid arthritis
5. Anti-cytokine therapy for rheumatoid arthritis
6. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc-fusion protein
7. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group
8. 54-week clinical and radiographic results from the attract trial: A phase III study of infliximab (Remicade™) in patients with active RA despite methotrexate
9. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial)
10. Management of patients with newly diagnosed rheumatoid arthritis
11. Recruitment of patients with early rheumatoid arthritis - The Netherlands experience
12. Diagnosis and course of early-onset arthritis: Results of a special early arthritis clinic compared to routine patient care
13. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year follow up on the hydroxychloroquine in early rheumatoid arthritis (HERA) study
14. Persistence of mild, early inflammatory arthritis
15. Inflammatory polyarthritis in the community is not a benign disease: Predicting functional disability one year after presentation
16. The outcome of knee synovitis in early arthritis provides guidelines for management
17. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
18. Association of HLA alleles and clinical features in patients with synovitis of recent onset
19. Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis
20. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) polymorphism related to joint damage in rheumatoid arthritis
21. Interleukin-10 microsatellite polymorphism and IL-10 locus alleles in rheumatoid arthritis susceptibility
22. Work disability associated with rheumatoid arthritis. The relative importance of disease, social, work, and family factors
23. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients
24. Can multidisciplinary team care preserve work capacity for patients with early rheumatoid arthritis?
25. Can multidisciplinary team care preserve work capacity for patients with early rheumatoid arthritis?
26. Smoking and risk of rheumatoid arthritis
27. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis
28. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: Result from a primary care based incident case-control study in Norfolk, England
29. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis
30. Does smoking influence disease outcome in patients with rheumatoid arthritis?
31. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial
32. A new national surveillance system for biologicals used for the treatment of RA
33. Access to disease modifying treatments for rheumatoid arthritis patients
34. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis
35. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: The EULAR Surveillance Register for Biological Compounds
36. Therapeutic exercise in rheumatoid arthritis
37. Radiographic outcome of recent-onset rheumatoid arthritis
38. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharpe's method (Van der Heijde modification)
39. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: Relationship to development of joint destruction in hands and feet
40. Radiographic damage in large joints in early rheumatoid arthritis: Relationship with radiographic damage in hands and feet, disease activity, and physical disability
41. Socio-economic consequences of rheumatoid arthritis in the first years of disease
42. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in the Netherlands
43. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset
44. Long-term course and outcome of functional capacity in rheumatoid arthritis
45. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
46. Economic consequences of the progression of rheumatoid arthritis in Sweden
47. The influence of HLA-DRBI genes on disease severity in rheumatoid arthritis
48. Prognostic implications of HLA genotyping in the early assessment of patients with rheumatoid arthritis
49. Rheumatoid arthritis and its animal models: The role of TNF-α and the possible absence of specific immune reactions
50. Identification of rat susceptibility loci for adjuvant-oil-induced arthritis
51. Inflammatory polyarthritis induced by mercuric chloride in the brown Norway rat
52. Antibodies to type II collagen in early rheumatoid arthritis
53. Quantifying the exact role of HLA-DRBI alleles in susceptibility to inflammatory polyarthritis. Result from a large, population-based study